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NATure IMMuNoLoGy CYBB) 1, 7 . Allelic heterogeneity at four of these ten loci (IFNGR1, IFNGR2, STAT1, and IL12RB1) has led to the description of 19 different genetic etiologies of MSMD 1 . Moreover, at five loci (STAT1, CYBB, NEMO, TYK2, and IRF8), MSMD is allelic to other clinical conditions associated with a broader range of infections 5, 8 . The discovery that MSMD results from inborn errors of IFN-γ immunity has revealed the critical dependence of human antimycobacterial immunity on IFN-γ . This finding has also confirmed that IFN-γ acts more as a macrophage-activating factor than as a classical interferon 9 . Moreover, the identification of patients with MSMD who are deficient in the cytokine IL-12p40 or the cytokine receptor IL-12Rβ 1 has revealed a critical dependence on the cytokines IL-12, IL-23, or both for the production of sufficient levels of antimycobacterial IFN-γ 1, 3, 10 . However, the genetic basis of this disease has remained elusive in almost half the patients with MSMD studied in our laboratory. The cellular basis of MSMD also remains unknown. In particular, it remains unclear which human myeloid and lymphoid cells orchestrate the production of IFN-γ for protective immunity to mycobacteria. In this context, we studied three patients with MSMD of unknown genetic etiology.
Results
Three patients with MSMD with homozygous splice mutations of SPPL2A. We investigated three patients from two unrelated consanguineous families: a family from Morocco including two affected eight-year-old monozygotic-twin sisters (P1 and P2, kindred A; Fig. 1a ) 11 and a family from Turkey including an affected 11-yearold boy (P3, kindred B; Fig. 1a ). All three children had BCG disease (clinical details in Methods). By combining whole-exome sequencing (WES) of P1 and P3 and genome-wide linkage for both families, we identified a homozygous essential splice-site mutation in SPPL2A (encoding signal peptide peptidase-like 2A, (SPPL2a)) in each family ( Supplementary Fig. 1a,b and Supplementary Table 1 ). There were no other relevant rare, nonsynonymous, or splice variants of protein-coding genes within the regions linked to MSMD (Supplementary Table 1 ). Sanger sequencing confirmed that both P1 and P2 carried a homozygous c.733+ 1G> A mutation of the splice donor site of SPPL2A intron 6, whereas P3 carried a homozygous c.1328-1G> A mutation of the splice acceptor site of SPPL2A intron 13 ( Fig. 1b and Supplementary Fig. 1b ). The familial segregation of these mutations was consistent with an autosomal recessive (AR) trait (Fig. 1a ). These mutations were not found in the gno-mAD database (http://gnomad.broadinstitute.org/) or our in-house database. The combined annotation-dependent deletion (CADD) scores of 27.3 (c.73+ 1G> A) and 26.4 (c.1328-1G> A) obtained for these two alleles are well above the mutation significance cutoff 12 of 2.31 ( Fig. 1c and Supplementary Fig. 1c ). Both family and population genetic studies thus strongly suggested that these three patients from two unrelated kindreds had AR SPPL2a deficiency.
Both SPPL2A mutations disrupt splicing of the full-length mRNA. We assessed the functional consequences of these two variants for the splicing of SPPL2A mRNAs, by performing RT-PCR on mRNA from Epstein-Barr virus-transformed B (EBV-B) cells of P1, simian virus 40-transformed fibroblasts (SV40 fibroblasts) from P2, peripheral blood mononuclear cells (PBMCs) from P3, and appropriate healthy controls both wild type (WT) and heterozygous for the corresponding mutation. We amplified a segment spanning exons 4-7 for kindred A and exons 13-15 for kindred B. The cells from all patients yielded PCR products of lower molecular weight than those obtained for healthy controls, whereas those of heterozygous carriers yielded both products (Fig. 1d ). Sanger sequencing of these PCR products showed that the c.733+ 1G> A (P1 and P2) mutation was associated with the complete skipping of exon 6 in the encoded mRNA, whereas the c.1328-1G> A (P3) mutation was associated with the complete skipping of exon 14 ( Fig. 1b ). Quantitative PCR showed that cells from the patients expressed approximately 25-40% the amount of SPPL2A mRNA found in healthy controls ( Supplementary Fig. 1d,e ). This finding is consistent with nonsense-mediated mRNA decay due to a premature stop codon (Fig. 1e ). We then transfected HEK293T cells with plasmids encoding a C-terminally V5-tagged WT protein or mutant SPPL2A cDNAs lacking exons 6 or 14 (Δ ex6 or Δ ex14, respectively). Immunoblotting with an antibody against amino acids 196-210 (a region preserved partially in Δ ex6 and completely in Δ ex14 SPPL2a proteins) revealed a protein product with an apparent molecular weight between 76 and 102 kDa for the WT construct ( Fig. 1f ). We detected no Δ ex6 SPPL2a protein and a protein of approximately 52 kDa for Δ ex14 SPPL2a, in agreement with the predicted molecular weight of the truncated protein (50 kDa) ( Fig. 1f ). Immunoblotting with an antibody against the C-terminal V5 tag showed both mutant proteins to be absent. These results indicated that both SPPL2A mutations disrupt mRNA splicing and lead to a loss of SPPL2a protein production (for the c.733+ 1G> A mutation causing Δ ex6) or to the production of a truncated protein (the c.1328-1G> A mutation causing Δ ex14) in an overexpression system. These findings strongly suggested that the patients had AR complete SPPL2a deficiency.
Accumulation of the N-terminal fragment of CD74 in
SPPL2a-deficient cell lines. SPPL2a is an intramembrane protease of the GxGD protease family 13 . Six proteins, TNF, CD74, FasL, TMEM106B, NRG1, and Bri2, have been identified as possible substrates of this enzyme [14] [15] [16] [17] [18] [19] [20] [21] [22] . A human gene connectome analysis of the genes encoding these proteins, taking IFNG as the core gene, identified TNF, CD74, and FASL as the only putative substrates significantly related to IFN-γ (http://hgc.rockefeller.edu/) 23 . Germline mutations of the human FAS and FASL genes underlie autoimmunity without mycobacterial disease 24, 25 . We assessed the effect of SPPL2a deficiency on TNF, a key cytokine for protective immunity against mycobacteria in humans 26 ( Supplementary Fig. 1f ). The mutations in our patients, compared with unaffected controls, resulted in the intracellular expression of TNF by a lower percentage of memory CD4 + T cells but had no effect on overall TNF secretion ( Supplementary Fig. 1g ,h). The normal amounts of secreted TNF were consistent with both SPPL2a cleaving the TNF NTF after its soluble segment has been released and the redundant function of SPPL2a and SPPL2b in that cleavage 15, 16 . We then considered CD74, the only substrate of SPPL2a previously confirmed in conditions of constitutive expression [19] [20] [21] 27, 28 . CD74 is expressed by HLA class II + antigen-presenting cells (APCs) 21 . In the endoplasmic reticulum, CD74 forms a heterotrimer with HLA class II α and β chains via the class II invariant-chain peptide (CLIP) region. CD74 is transported to the endosomal compartments, where it is processed by four successive proteolytic cleavages, thus leaving the class II invariant-chain peptide fragment associated with the HLA class II molecule and a standalone membrane-bound NTF. In the final step of CD74 processing, SPPL2a mediates the intramembrane cleavage of the NTF (Fig. 2a ) [19] [20] [21] . We evaluated the functional consequences of SPPL2a deficiency in patients by assessing CD74 NTF accumulation in various cell types ex vivo and in cell lines in vitro, with an antibody recognizing amino acids 12-28 in the N terminus of human CD74. We found that CD74 NTF levels were much higher in EBV-B cells from P1, IFN-γ -stimulated SV40 fibroblasts from P2, and PBMCs from P3, than in the corresponding cells from healthy donors and SPPL2A-heterozygous relatives (Fig. 2b,c ). We used a retroviral system to introduce the WT SPPL2A allele into EBV-B cells from P1; this allele rescued the phenotype of CD74 NTF accumulation ( Fig. 2c ). We also tested all eight SPPL2A variants found in the homozygous state according Articles NATure IMMuNoLoGy to public databases and found that all of those variants rescued CD74 NTF accumulation (Figs. 1c,e and 2d). Moreover, the addition of two inhibitors of SPPL2a function, L-685,458 and (Z-LL) 2 -ketone, led to the accumulation of CD74 NTF in EBV-B cells from healthy individuals, albeit to a lower extent than in SPPL2a-deficient EBV-B cells ( Fig. 2e ). No CD74 NTF accumulation was observed with another inhibitor (DAPT), which had no inhibitory effects on SPPL2a ( Fig. 2e ). As previously reported, inhibitors of cathepsin (E64d) stabilized larger intermediates of CD74 degradation ( Fig. 2e) 29 . These results confirmed the complete functional deficiency of SPPL2a, in terms of CD74 NTF cleavage, in the three patients. They also demonstrated that the frequency of SPPL2a deficiency in the general population is well below that in people with MSMD (approximately 10 -5 ).
Collectively, these findings showed that the two SPPL2A mutations underlie AR SPPL2a deficiency in these two kindreds.
Accumulation of CD74 NTF in SPPL2a-deficient leukocytes.
We further analyzed the cell type-specific effects of SPPL2adependent CD74 NTF accumulation. We first used flow cytometry to determine the intracellular CD74 levels in primary monocytes and B and T cells. We observed that intracellular CD74 staining was stronger in monocytes and B cells from SPPL2a-deficient patients than from healthy controls and heterozygous relatives, whereas no such difference was observed for T cells ( Fig. 2f and Supplementary Fig. 2a,b ). This stronger staining presumably reflects the accumulation of NTF observed on immunoblots of EBV-B cells, PBMCs, and SV40 fibroblasts S top  c.1328-1G>A  c.733+1G>A   1  1 5  14  13  12  11  10  9  8  7  6  5  4  3  2   SPPL2A gene   I   II   1  2   1  2  3   Kindred A  c.733+1G>A   I   II   1 In red, M denotes the mutation in each family, as indicated above each pedigree. Solid symbols indicate affected individuals. b, Schematic representation of the SPPL2A gene. Each numbered box represents an exon. The mutations studied here are marked in red. Black exons were spliced out because of the mutations. c, CADD score (y axis) plotted against minor allele frequency (MAF, x axis) for the mutations found in our patients and homozygous variations described in the gnomAD database. MSC, mutation significance cutoff. d, PCR of exons 4-7 and 13-15 of SPPL2A cDNA from SV40 fibroblasts (SV40-F), EBV-B cells, and PBMCs from healthy controls, the three patients and their relatives. GF is the paternal grandfather (WT/WT), and F is the father (WT/M) from kindred B. Water was used as a negative control (C -). Results shown are representative of two independent experiments. e, Schematic representation of the structure of WT SPPL2a, in which the variants from c are indicated. The schemes in the lower part of the figure show the predicted consequences of the mutations. Each mutation causes a frameshift leading to a predicted noncanonical sequence indicated in red and a premature stop codon, at positions 219 and 452. f, Immunoblot analysis of SPPL2a in HEK293T cells either nontransfected (NT) or transfected with an empty vector (EV), WT SPPL2A, SPPL2AΔ ex6, or SPPL2AΔ ex14 all C-terminally V5 tagged. MW, molecular weight. Two antibodies were used: anti-SPPL2a N terminus and an anti-V5 tag. GAPDH served as a protein loading control. Results shown are representative of three independent experiments.
Articles
NATure IMMuNoLoGy ( Fig. 2c ). We then measured cell-surface CD74 expression on these same leukocyte subsets, with an antibody against the extracellular domain of CD74. CD74 expression on the surfaces of monocytes, B cells, and T cells did not differ significantly between SPPL2a-deficient patients and healthy controls ( Fig. 2g and Supplementary Fig. 2a ,c). We then identified the leukocyte 
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subsets with the highest amounts of CD74 NTF accumulation, by treating PBMCs from healthy controls with L-685,458, an inhibitor of SPPL2a. The CD1c + subset of conventional dendritic cells (cDC2s) accumulated the highest amount of CD74 NTF ( Fig. 2h and Supplementary Fig. 2d ). Circulating CD141 + Clec9a + conventional dendritic cells (cDC1s), CD303 + plasmacytoid dendritic Supplementary Fig. 4a , with quantification as a percentage of PBMCs and as cells/ml, with the normal range values from ref. 51 shown as a dashed square, for cDC2s (a-c), cDC1s (d-f), and pDCs (g-i). j, Total frequency of myeloid DCs. The two AD IRF8-deficient patients were immunophenotyped twice for b, h, and j, but only individual values were used for statistical analysis. An unpaired two-tailed t test with 95% confidence was used (*P < 0.05). Nonsignificant results are not shown. All graphs show the mean with or without s.e.m. All these experiments were performed twice with identical results, with the exception of cDC1 immunophenotyping for AR IRF8-deficient patients for d-f, which was performed once. Each dot represents the value obtained from a different individual unless indicated otherwise. Supplementary Fig. 5a ,b. b, Frequency of CD34 + HLA-DR + progenitors in healthy controls and SPPL2a-deficient patients. Gating is shown in Supplementary Fig. 4d . c, Frequency of early pre-DCs in healthy controls and SPPL2a-deficient patients. Gating is shown in Supplementary Fig. 4f . d, Differentiation potential of granulocyte, monocyte, and DC progenitors in MS-5 stromal cells plus cytokines cultured with or without SPPL2a inhibitor (L-685,458), DAPT, or DMSO vehicle control. e, Percentage of dead cells, for single CD45 + cells either untreated or treated with L-685,458, DAPT, or DMSO. f, Intracellular CD74 levels in cDC1s, cDC2s, pDCs, and monocytes, after the in vitro differentiation from granulocyte, monocyte and DC progenitors, with or without L-685,458, DAPT, or DMSO. g, MFI for intracellular CD74 (iCD74) from f, normalized to the values of the untreated samples to show fold accumulation. (An unpaired two-tailed t test with a 95% confidence was used (*P < 0.05; **P < 0.01), comparing values from healthy controls and patients (n = 3). Nonsignificant results are not shown. All graphs show the mean with or without s.d. Immunophenotyping for a-c was done once. In d, f, and g, representative results of one out of three experiments are shown. Each dot represents the value obtained from a different individual for a, b, and c, or experiment for e). [19] [20] [21] . SPPL2a-deficient mice are probably susceptible to pyogenic bacteria 31 . None of the three patients described here had a B cell deficiency other than slightly lower total IgG levels and, in P1 and P2, slightly higher IgM levels than those in age-matched controls ( Supplementary Tables 2 and 3 ). P3 had normal specific-antibody titers against vaccine antigens and mounted specific antibody responses after infection with viruses (Supplementary Table 2 ). After inoculation with conjugated pneumococcal vaccines, the three patients mounted normal antibody responses against some, but not all, serotypes of pneumococcal glycans (Supplementary Table 2 ). In addition, they had normal proportions of peripheral CD19 + B cells, including transitional, naive, and memory B cells, whereas Sppl2a -/mice displayed a severe B cell deficiency after transitional stage 1 ( Supplementary Fig. 3a,b and Supplementary Tables 2-4 ). The expression of CD21, IgM, and IgD was normal in the patients' SPPL2a-deficient B cells (data not shown). The percentage of IgG + memory B cells was slightly lower in SPPL2a-deficient patients than in age-matched healthy individuals, but the percentage of IgA + memory B cells was normal ( Supplementary Fig. 3c ). We sorted naive and memory B cells from SPPL2a-deficient patients, heterozygous relatives, and healthy controls, and stimulated them with CD40L together with IL-21. In contrast to reported results for Sppl2a -/mice [19] [20] [21] , the secretion of IgM, IgG, and IgA by B cells from patients was similar to that in healthy controls ( Supplementary Fig. 3d ). Moreover, unlike B cells from Sppl2a -/mice [19] [20] [21] , the SPPL2a-deficient B cells of the patients had normal surface expression of the receptors HLA-DR and BAFF-R ( Supplementary Fig. 3e ). Finally, the patients displayed none of the pyogenic infections typical of human B cell deficiencies 32 , thereby providing further evidence of their adequate B cell development, differentiation, and function despite CD74 NTF accumulation. Thus, SPPL2a deficiency in humans appears to differ from the corresponding mouse model in its minimal effect on B cells and humoral immunity in the three children studied.
Human SPPL2a deficiency affects type 2 conventional dendritic cells. Sppl2a -/mice have a profound deficit in CD11c + CD11b + cDCs [19] [20] [21] , which are the equivalent of human CD1c + cDC2s 33 . This lack of CD11c + CD11b + cDCs is CD74 dependent, because CD74 deficiency restores these cells in Sppl2a -/mice 19 . Three main subsets 
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NATure IMMuNoLoGy of dendritic cells (DCs) are present in human blood: cDC2s, cDC1s, and pDCs 34 . We analyzed these three circulating DC subsets in controls and SPPL2a-deficient patients. All patients had a significantly lower frequency of CD1c + CD11c hi HLA-DR hi cDC2s than controls, and marginally lower frequencies of CD141 + Clec9a + cDC1s, but normal frequencies of pDCs ( Fig. 3a-i and Supplementary Fig. 4a,b ). Total cDC (CD11c + ) frequencies were also lower in patients than in controls (Fig. 3j) . These results suggest that humans with AR SPPL2a deficiency have a selective loss of cDC2s. The remaining CD1c + cells in the patients, compared with controls, also displayed elevated HLA-DR expression at the cell surface ( Supplementary  Fig. 4c,d) , as previously shown in Sppla2 -/mice 20 . CD74 NTFmediated toxicity probably triggers an unfolded-protein response, thereby inducing expression of the endoplasmic reticulum-stress sensor XBP1, which is an inducer of MHC II expression 35 . Strikingly, the selective cDC2-deficiency phenotype of these patients resembles that previously observed in the two patients with MSMD with AD partial IRF8 deficiency (Fig. 3a-c) 30 . However, an analysis of cDC1s within the CD11c + gate, by using antibodies to CD141 and Clec9a, showed that the DC defect in these patients was not restricted to cDC2s. Instead of the two populations seen in healthy controls, the AD IRF8-deficient patients had just one Clec9apopulation with abnormally high CD141 expression ( Fig. 3d and Supplementary  Fig. 4a ). The lower frequency of CD1c hi cDC2s observed in both AR SPPL2a-deficient and AD IRF8-deficient patients was not due to low CD1c expression, because the CD1c -DC population of healthy controls as well as SPPL2a-or IRF8-deficient patients contained no HLA-DR hi CD11c hi cells, which bear two markers characteristic of cDC2s ( Supplementary Fig. 4e ). In addition, in contrast to the very high plasma concentrations of the cytokine Flt3 ligand found in patients with AD GATA2 deficiency and AR IRF8 complete deficiency, who lack multiple types of circulating DCs 30, 36 , patients with AD IRF8 and AR SPPL2a deficiency had normal circulating levels of Flt3 ligand ( Supplementary Fig. 4f ). Because cDC2s are potent producers of IL-12 and IL-23 (ref. 37 ), we tested the ability of these patients to produce IL-12p40, a subunit common to these two cytokines 38 . We stimulated whole blood from healthy controls and SPPL2a-deficient patients with BCG, IFN-γ , or both, and measured IL-12p40 production. We observed no defect in IL-12p40 production in patients with AR SPPL2a deficiency, thus suggesting that the low frequency of cDC2s in these patients does not cause overt IL-12 and IL-23 defects in the stimulation conditions used 30 
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( Supplementary Fig. 4g ). Collectively, these data indicated that patients with AR SPPL2a deficiency had a defect in the cDC2 compartment that did not prevent their whole blood from producing IL-12p40 in response to BCG and IFN-γ .
The role of SPPL2a in DC development. We analyzed DC development in the setting of SPPL2a deficiency by assessing the frequencies of CD34 + progenitors and HLA-DR + precursors among the patients' PBMCs. We found normal frequencies of total CD34 + Linprogenitors ( Supplementary Fig. 5a ), including hematopoietic stem cells/ multipotent progenitors, megakaryocyte-erythroid progenitors, granulocyte-monocyte progenitors, lymphoid-primed multipotent progenitors, multilymphoid progenitors, and B cell-NK progenitors, and slightly lower frequencies of common myeloid progenitors, in the patients than in healthy controls ( Fig. 4a and Supplementary  Fig. 5a,b) . However, the patients had significantly lower frequencies of CD34 + HLA-DR + cells ( Fig. 4b and Supplementary  Fig. 5d,e ). Furthermore, among the Lin(CD3, CD19, CD56, CD14, CD16) -HLA-DR + cells, a population including early DC precursors 39, 40 , CD34 -CD1c -Clec9a -CD123 + CD303 + CD141 + CD45RA +/int early pre-DCs 39 were significantly less frequent in SPPL2a-deficient patients than in healthy controls ( Fig. 4c and Supplementary  Fig. 5f ). This result suggests that SPPL2a deficiency impedes DC development at the pre-DC stage, when HLA-DR expression is initiated. We then purified CD34 + cells from healthy-donor cord blood and generated DCs in vitro with the cytokines GM-CSF, SCF, and Flt3 ligand 41 , with or without the SPPL2a inhibitor L-685,458. SPPL2a inhibition had no effect on the numbers, proportions, or viability of cDC1s, cDC2s, or pDCs on day 6 of differentiation ( Fig. 4d,e ). However, the increase in intracellular CD74 relative to untreated cells was larger in cDC2s than in the other subsets analyzed, thus demonstrating that NTF accumulation was due to the inhibition of SPPL2a (Fig. 4f,g) . These data suggested that residual SPPL2a activity in the presence of the inhibitor might be sufficient for the development of cDC2s in vitro, but not in patients with the corresponding null genetic defect in vivo. Our data indicated that the chemical inhibition of SPPL2a in peripheral leukocytes from healthy donors ex vivo ( Fig. 2e ) and during DC differentiation from peripheral stem cells in vitro resulted in the preferential accumulation of CD74 NTF in cDC2. Moreover, the frequency of DC progenitors was low in SPPL2a-deficient patients from the first stages of HLA-II expression, in agreement with the role of CD74 in correct assembly of the HLA-II complex. These findings strongly suggested that the mechanism underlying the paucity of cDC2 cells in SPPL2a-deficient patients involved CD74 NTF toxicity, as demonstrated in the mouse model 19, 20 .
Normal development of CD4 + helper T cells.
SPPL2a is expressed strongly in APCs but only weakly in T cells ( Fig. 5a and Supplementary Fig. 2d ), thus suggesting that an intrinsic T cell defect is unlikely in SPPL2a-deficient patients. However, given the very low frequency of circulating cDC2s, we hypothesized that the cytokine production ability of SPPL2a-deficient CD4 + helper T cells might be impaired, owing to a defect in the differentiation of naive cells into memory cells in vivo. The three patients had normal counts and proportions of the various circulating T cell subsets: total CD3 + ; naive and memory CD4 + ; Table 3 ). Moreover, the distribution of the different subsets of memory helper T cells (T H 1, T H 2, T H 17, and T H 1*), as determined by surface phenotype (CCR6, CCR4, and CXCR3), was normal (Fig. 5b,c) . Naive and memory CD4 + T cells from healthy individuals and AR SPPL2a-deficient patients were isolated and cultured with T cell activation and expansion (TAE) beads, and cytokine production was measured after 5 d (ref. 42 ). No differences were observed in the production of the cytokines IFN-γ , IL-4, or IL-17F between memory CD4 + T cells from SPPL2a-deficient individuals and those from healthy donors (Fig. 5d ). T H 1 differentiation is IL-12 dependent, whereas T H 17 differentiation is IL-23 dependent 43 . We then assessed intrinsic defects in CD4 + T cell differentiation due to SPPL2a deficiency, by culturing naive CD4 + T cells in the presence of TAE beads alone (T H 0) or under T H 1-, T H 2-, or T H 17-polarizing conditions. No impairment in polarization ability was observed by measuring the increase in IFN-γ , IL-10, or IL-17F production between naive and polarized helper T cells, thus suggesting that helper T cell function is not globally impaired in patients with AR SPPL2a deficiency (Fig. 5e) . Given the similarities between AR SPPL2a and AD IRF8 deficiencies, we analyzed CD4 + T cell function in a patient with AD IRF8 deficiency in a similar manner. No impairment in IFN-γ , IL-13, or IL-17A production relative to that in healthy controls was observed for the patient's CD4 + T cells, thus suggesting that the cells' polarization ability was also intact (Fig. 5f ). However, when memory CD4 + T cells from AD IRF8deficient patient were isolated and cultured with TAE beads for 5 d, the levels of T H 1 cytokines (IFN-γ and TNF), T H 2 cytokines (IL-4, IL-5, and IL-13), and T H 17 cytokines (IL-17A, IL-17F, and IL-22) were lower than those for healthy-control cells, thus suggesting that AD IRF8 deficiency impairs the maintenance of the CD4 + T cellmediated memory response or that these cells undergo limited differentiation in vivo (Fig. 5g ). In conclusion, SPPL2a deficiency does not result in any major CD4 + T cell phenotype, as measured ex vivo, whereas AD IRF8 deficiency causes a broad defect in the CD4 + memory T cell compartment.
regulatory T cells; follicular helper T cells; and CD8 + naive, central, and effector memory T cells; γ δ T cells; and mucosal-associated invariant T cells (Supplementary
Impaired production of IFN-γ by mycobacterium-specific memory CD4 + T cells.
We investigated subtler defects in T cell responses to mycobacteria by isolating two subsets of memory CD4 + T cells from healthy controls and patients with AR SPPL2a or AD IRF8 deficiency, as determined on the basis of CCR6 expression 44 . The polyclonal CD4 + CCR6 + (comprising T H 17 and T H 1*) and CD4 + CCR6 − (comprising T H 1 and T H 2) memory T cell populations were initially expanded in multiple wells by incubation with IL-2 and phytohemagglutinin 45 . The CD4 + CCR6 + and CD4 + CCR6polyclonal T cell lines from patients and controls displayed the same frequencies of IFN-γ + cells after stimulation with phorbol myristate acetate (PMA) plus ionomycin and produced equal amounts of IFN-γ after activation with PMA and ionomycin, or anti-CD3/28 antibodies ( Supplementary Fig. 6a-f ). The T cell lines were then analyzed for reactivity to viral, bacterial, and fungal antigens presented by autologous irradiated B cells, as measured by [ 3 H]thymidine incorporation. The frequencies of CD4 + CCR6 + T cells reacting with antigens from BCG or MTB were higher in patients with SPPL2a deficiency than in healthy controls (Fig. 6a) . In contrast, BCG-or MTB-specific cells were less frequent or were absent in patients with AD IRF8 deficiency (Fig. 6a ). SPPL2a-deficient patients had a high frequency of CD4 + CCR6 -T cells against viral antigens (CMV, EBV, influenza, and RSV), whereas the frequency of these cells was variable in healthy donors and IRF8-deficient patients, a result possibly reflecting differences in exposure or vaccination ( Supplementary  Fig. 6g ). Notably, in patients with SPPL2a deficiency, IFN-γ production was much weaker in CD4 + CCR6 + T cells responding to BCG or MTB antigens (Fig. 6b,c) , whereas IFN-γ production by CD4 + CCR6 -T cells responding to viral antigens was similar to that of healthy donors (Fig. 6d) . The IFN-γ production defect was also observed in BCG-responding CD4 + CCR6 -T cells ( Supplementary Fig. 6h,i) . These data suggested that SPPL2a-deficient patients displayed a mycobacterium-specific IFN-γ production defect by memory CD4 + T cells. We confirmed that the responding T cell lines were actually T H 1* cells expressing the characteristic CCR4, CXCR3, and CCR6 markers ( Supplementary Fig. 6j ). The few mycobacterium-specific CD4 + CCR6 + T cells from patients with AD IRF8 deficiency also Articles NATure IMMuNoLoGy displayed low IFN-γ production (Fig. 6b,c) . IRF8-mutated virus-specific CD4 + CCR6 -T cells also displayed weak IFN-γ production, thus suggesting a broader defect in memory T cells in these patients than in SPPL2a-deficient patients (Fig. 6d ). This finding is consistent with those from the study of ex vivo cytokine production by CD4 + memory T cells described above. The strong accumulation of CD74 NTF in the B cells used might have affected their ability to act as APCs. We therefore pulsed EBV-B cells from P1, either nontransduced or transduced with a retrovirus generated with an empty vector or a WT SPPL2A cDNA, with MTB peptides (which do not require processing) or whole MTB antigens (which require processing), then used the cells as APCs to stimulate MTB-specific T cell clones from P1 and P2. There were no differences in the proliferation of T cells, thus suggesting that the ability of patient B cells to take up whole antigens and to present the processed peptides was intact ( Supplementary Fig. 6k ). Similar results were obtained when influenza vaccine was used to stimulate influenza-specific T cell clones ( Supplementary Fig. 6k ). Collectively, these data showed that SPPL2a-deficient patients displayed a narrow immunological phenotype, with abnormally small numbers of cDC2s and poor IFN-γ production by mycobacteriumspecific T H 1* cells. In contrast, IRF8-mutated patients displayed a broader immunological phenotype but had two features in common with SPPL2a-deficient patients: low numbers of cDC2s and impaired IFN-γ production by mycobacterium-specific T H 1* cells.
IRF8 controls SPPL2A expression. Given the phenotypic similarities between AR SPPL2a and AD IRF8 deficiencies, we hypothesized that there might be a physiological connection between SPPL2a and IRF8. We investigated whether mouse IRF8 exerted transcriptional control over Sppl2a expression. We performed chromatin immunoprecipitation-sequencing (ChIP-seq) analyses on mouse bone marrow-derived macrophages and peritoneal macrophages. We found binding sites for STAT1, IRF1, and IRF8 in the Sppl2a promoter, thus suggesting that the expression of mouse Sppl2a is under the control of these transcription factors ( Supplementary  Fig. 7a ) 46, 47 . We analyzed EBV-B cells from healthy controls, and patients with AR complete STAT1, IRF8, and SPPL2a deficiencies. We found that SPPL2a expression was slightly weaker than that in normal in EBV-B cells lacking functional IRF8, a result consistent with the ChIP-seq data obtained for mice ( Supplementary Fig. 7b ). We also analyzed the SPPL2a expression of total lymphocytes, B cells, and T cells from two patients with AD IRF8 deficiency. We found no differences between these patients and healthy controls, a result consistent with both the partial nature of AD IRF8 deficiency and the expression of IRF8 predominantly in cDC1s and cDC2s, two subsets lacking in these patients ( Supplementary Fig. 7c,d) . Our data show that mouse IRF8 binds the Sppl2a promoter and suggest that the human ortholog may control SPPL2A transcription.
Sppl2a -/mice are susceptible to mycobacterial infection. We investigated the role of mouse SPPL2a in protective immunity to mycobacteria in vivo, by infecting WT and Sppl2a -/mice with live BCG. Sppl2a -/mice have low frequencies of CD11c + CD11b + cDC2s ( Fig. 7a and Supplementary Fig. 7e ). Sppl2a -/mice developed significantly greater splenomegaly than WT mice three and six weeks after infection, and significantly higher BCG colony-forming unit (CFU) counts were obtained six weeks postinfection, thus indicating greater susceptibility to BCG infection (Fig. 7b,c) . Both the size of the IFN-γ + CD4 + and CD8 + T cell fraction and the production of IFN-γ by splenocytes (after stimulation with BCG or PMA-ionomycin) at 3 and 6 weeks postinfection were much lower in Sppl2a -/mice than in WT controls (Fig. 7d) . Sppl2a -/-CD4 + and CD8 + T cells also produced less TNF than did WT cells (Fig. 7e ). Mouse CD4 + T cells mount a classical T H 1 response to mycobacterial infection, which differs from the T H 1* response observed in humans. We cannot therefore conclude that the impairment in IFN-γ production in mice was due to T H 1* cells. Nevertheless, these experiments show that mouse SPPL2a is required for optimal IFN-γ production by T cells after mycobacterial infection. We also infected Sppl2a -/and WT mice with MTB aerosol. At 200 d postinfection, all WT mice remained alive, whereas all the Sppl2a -/mice had died (Fig. 7f ). Mice infected with MTB aerosol had higher lung MTB CFU counts 60 d after infection (Fig. 7g) . The total number of cells in the lungs and the numbers of CD4 + T cells, CD8 + T cells, CD11b + Ly6C + monocytes, and CD11b + F4/80 + macrophages were higher than those in WT mice 60 d after infection, and the numbers of neutrophils and CD11b + Ly6C + monocytes were already higher than those in WT mice 30 d after infection (Fig. 5h-m and Supplementary  Fig. 7e ). Sppl2a -/mice produced larger amounts of IFN-γ , TNF, and IL-12p40 than did WT mice, as shown by analyses of lung homogenates, in agreement with the higher leukocyte infiltration into the lungs in these mice (Fig. 7n) . Thus, Sppl2a -/mice lack CD11b + CD11c + cDCs (cDC2s) and are susceptible to both BCG and MTB infections in vivo, and their T cells produce low levels of IFN-γ after mycobacterial infection in vivo.
Discussion
Here, we described AR complete SPPL2a deficiency, which is a new genetic etiology of MSMD. We also showed that Sppl2a -/mice are susceptible to BCG and MTB. Impairment in SPPL2a activity through either genetic or pharmacological means causes CD74 NTF to accumulate in H-2 and HLA class II + APCs in mice and humans, respectively. This accumulation leads to a profound B cell deficiency in Sppl2a -/mice [19] [20] [21] but not in SPPL2a-deficient humans. In contrast, both mice and humans with SPPL2a deficiency have a profound defect in the cDC2 compartment. This myeloid phenotype is due to CD74 NTF accumulation, because NTF levels in cDC2s are highest after the pharmacological inhibition of SPPL2a in healthy donor cells. Moreover, circulating pre-DC progenitors have low abundance in SPPL2a-deficient patients, from the first stage of HLA-class II expression. Finally, the cDC2 deficiency has been rescued in vivo by the genetic ablation of CD74 in Sppl2a -/mice [19] [20] [21] .
A complete lack of the three main circulating DC subsets (cDC1s, cDC2s, and pDCs) has been observed in patients with AD GATA2 or AR IRF8 deficiency, both of which cause mycobacterial disease and other infections 30, 48 . AD IRF8 deficiency, a genetic etiology of MSMD, was previously thought to cause an isolated defect in circulating CD1c + cDC2 cells 30 . However, our present analysis revealed that both types of conventional DCs-cDC1s and cDC2s-are actually affected in these patients. In contrast, AR SPPL2a deficiency results in an isolated cDC2 defect, thus highlighting the crucial role of this human DC population in antimycobacterial immunity. We also found that patients with AR SPPL2a deficiency have a profound defect in mycobacterium-specific IFN-γ production by the CD4 + memory T cells of the T H 1* subset. Paradoxically, the T H 1* cell counts were normal in the blood of these patients, and these cells proliferated normally in response to mycobacterial antigens and produced IFN-γ after polyclonal mitogenic stimulation in vitro. Moreover, our study indicated that patients with AD IRF8 deficiency also have a more severe memory CD4 + T cell defect, with poor proliferation of T H 1* cells in response to mycobacterial antigens in vitro. Nevertheless, the clinical phenotype of MSMD is identical in patients with these two deficiencies. Despite some immunological differences between AR SPPL2a-deficient patients and AD IRF8deficient patients, these two genetic diseases share three core phenotypes: a defect in cDC2, a defect in mycobacterium-specific T H 1* cells, and a clinical phenotype of MSMD. These findings suggest that cDC2 and T H 1* cells play an essential role in human antimycobacterial immunity. The link between these two disorders is highlighted by the observation that transcription of the mouse Sppl2a gene is controlled by various transcription factors including IRF8. We also found that SPPL2a levels were slightly lower than normal in Articles NATure IMMuNoLoGy EBV-B cells with complete IRF8 deficiency. IRF8 is probably more critical for the expression of SPPL2a in DCs. However, these cells are lacking in patients with either AR or AD IRF8 deficiency, thus making assessment of SPPL2a expression in IRF8-deficient myeloid cells impossible.
Our findings suggest that cDC2s may be the key cells presenting mycobacterial peptide antigens to CD4 + T cells. The cDC2 deficiency in patients with AR SPPL2a deficiency might cause defective priming in mycobacterium-specific T H 1* cells. The normally high IL-12 and IL-23 production by cDC2 cells is probably relevant 37 . Indeed, AR deficiencies in IL-12p40 or IL-12Rβ 1 underlie MSMD 1, 3, 10 . Defective IL-12 and IL-23 stimulation in the course of T cell priming might prevent the correct development of T H 1* cells in patients with AR SPPL2a deficiency. Overall, our findings suggest that cDC2s are required in vivo for T H 1* priming after the presentation of mycobacterial antigens. There is probably a causal relationship between the global cDC2 and narrow T H 1* phenotypes in these patients, given the multiple known relationships between the cells involved (DC and helper T) and their relevant products (IL-12, IL-23, and IFN-γ ). The myeloid and lymphoid phenotypes are both broader in patients with IRF8 deficiency than in those with SPPL2a deficiency, thus further supporting a connection. The core myeloid phenotype, with a global cDC2/IL-12/IL-23 defect, the core lymphoid phenotype, with a mycobacterium-specific T H 1*/IFNγ defect, or both might also cause a clinical phenotype of MSMD in other patients 1, 3, 10 . In addition, SPPL2a may possibly be required for the proper expression of other antimycobacterial molecules 49, 50 . Further genetic and immunological studies of patients with unexplained MSMD are required to more accurately delineate the molecular and cellular basis of protective immunity to mycobacteria in humans.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0178-z.
Articles
NATure IMMuNoLoGy
Methods
Patients and clinical information. Two of the patients studied (P1 and P2) are twins born in 2009 to first-cousin Moroccan parents. They were vaccinated with BCG at birth and presented with unilaterally enlarged and inflammatory axillary lymph nodes at nine months of age. The enlarged lymph nodes were surgically removed. Biopsy confirmed the presence of acid-fast bacilli, a finding consistent with mycobacterial infection. P1 and P2 had normal counts of neutrophils, monocytes, CD19 + B cells, CD3 + , CD4 + , CD8 + T cells, and NK cells. No immunoglobulin, respiratory burst, or complement defects were found (Supplementary Table 3 ). No complications had been observed during the pregnancy, but neonatal asphyxiation was noted during the delivery. MSMD was subsequently diagnosed. Neither of the patients had experienced any other episodes of mycobacterial infection by the time of clinical evaluation at three years of age. In addition to MSMD, the patients displayed hereditary spastic paraplegia due to a homozygous p.R1105X mutation of the AP4E1 gene 11 .
P3 is a boy born to first-degree consanguineous parents in Turkey in 2007. He presented with a two-month history of left axillary lymphadenopathy. He was vaccinated with BCG, on the left shoulder, at the age of two months. At the age of six months, he was treated with isoniazid after a positive tuberculin skin test (22 × 22 mm), possibly because of contact with his aunt, who had active pulmonary TB. He had a normal thoracic computed tomography scan at the time. His parents and brother are healthy. His aunt, grandfather, great uncle, and great aunt had had pulmonary TB. The physical-examination findings were unremarkable, with the exception of an enlarged lymph node (3 × 3 cm) in the left axillary region. The leukocyte count, absolute neutrophil count, and absolute lymphocyte count were normal. The serum IgG was low (Supplementary Table 2 ), whereas the serum IgA, IgM, and IgE were normal for the patient's age. The peripheral blood lymphocyte subsets were normal. The neutrophil function in the neutrophil oxidative burst assay results were normal. The CD212 (IL-12Rβ 1) expression was normal (CD212, 83%; control, > 80%) on the surface of activated T cells. The tuberculin skin test was positive (10 × 10 mm). The enlarged axillary lymph node was excised and dissected. Large amounts of calcified material were drained from the lymph node during dissection. Histological examination revealed a necrotizing granulomatous inflammation. Ziehl-Neelsen staining revealed the presence of acid-fast bacilli. MTB complex PCR and culture were negative. A diagnosis of MSMD was made, and antimycobacterial tritherapy was initiated. P3 is now 11 years old and remains free from mycobacterial disease and other infectious diseases.
Ethics statement. The study was approved by and performed in accordance with the requirements of the institutional ethics committees of Necker-Enfants Malades Hospital, Paris, France, and The Rockefeller University Hospital, New York, USA. Informed consent was obtained for all patients and healthy control volunteers reported in the study.
Cell culture and cell isolation. HEK293T cells and SV40 fibroblasts were cultured in DMEM (Gibco) supplemented with 10% FCS. Phoenix A retroviral packaging cells were cultured in IMDM (Gibco) supplemented with 10% FCS. EBV-B cells were cultured in RPMI (Gibco) supplemented with 10% FCS. PBMCs were isolated with Ficoll-Paque PLUS (GE Healthcare) centrifugation and cultured in RPMI (Gibco) supplemented with 10% FBS. All cell lines used tested negative for mycoplasma. HEK293T and Phoenix A cells were purchased from the ATCC. B cells and fibroblasts from healthy controls or patients were immortalized in house with EBV and SV40 virus, respectively. None of the cells described above were authenticated, but the genotypes at the sites of the mutations studied in this report were confirmed.
SPPL2a overexpression.
A WT SPPL2A plasmid was purchased from Origene, and SPPL2A was excised and inserted into a pcDNA3.1-V5 (Invitrogen) or pLZRSiresΔ NGFR (Addgene) plasmid. pLZRSiresΔ NGFR containing WT SPPL2A, the mutants studied in this report (Δ ex6 and Δ ex14), or the variants described in genomAD (http://gnomad.broadinstitute.org/) was used to transfect Phoenix A cells, and retroviruses were produced and used to transduce EBV-B cells from P1, as previously described 52 . HEK293T cells were transfected in the presence of Lipofectamine LTX reagent (Invitrogen), with pcDNA3.1-V5 containing WT SPPL2A or the mutant cDNAs studied here.
SPPL2a inhibition in EBV-B cells or PBMCs.
Freshly isolated PBMCs or EBV-B cells (10 6 cells/ml) in RPMI supplemented with 10% FCS were incubated with or without 1 μ M DMSO, 1 μ M gamma secretase/SPPL inhibitor L-685,458 (EMD Millipore), 10 μ M (Z-LL)2-ketone (Santa Cruz), 10 μ M calpain activation inhibitor E64d (Santa Cruz), or 10 μ M DAPT (another gamma secretase inhibitor, from R&D Systems) for 5 h for cytokine production and for 24 h to study CD74 accumulation at 37 °C, to mimic the conditions of SPPL2a deficiency.
Immunoblotting. Proteins were extracted with whole-cell-lysis buffer containing 20 mM Tris-HCl, pH 7.4, 140 mM NaCl, 2 mM EDTA, 50 mM NaF, and 1% NP-40 supplemented with protease-inhibitor cocktail (Complete mini, Roche); proteins were quantified with the Bradford assay. Lysates (50 μ g of protein) were mixed with Laemmli loading buffer and incubated at 55 °C for 5 min before being subjected to electrophoresis in a 4-12% acrylamide precast SDS-PAGE gel (Bio-Rad). The following antibodies were used for immunoblotting: rabbit anti-human SPPL2a C-terminus 53 , rabbit anti-human SPPL2a epitope 8 (ENLKAVTTEDREMRK, residues 196-210 of human SPPL2a, provided by B.S.), anti-CD74 (ab97479, Abcam), anti-GAPDH HRP (sc-25778, Santa Cruz), and anti-V5-HRP (R96125, Invitrogen).
ELISA for human cytokines. Flt3 ligand, TNF, and IL-12p40 levels were determined by ELISA with commercial kits, according to the manufacturer's instructions (R&D Systems).
Flow cytometry and Imagestream. Intracellular CD74, IRF8, and SPPL2a levels were determined in various subsets of PBMCs, by first distinguishing between live and dead cells with LIVE/DEAD fixable aqua (Life Technologies) and then by staining for surface markers with anti-CD4 APC/Cy7 (RPA-T4, 300518, BioLegend), anti-CD8 V450 (RPA-T8, 560347, BD), anti-CD45RO Percp/ Cy5.5 (UCHL1, 560607, BD Biosciences), anti-CCR7 PE/Cy7 (G043H7, 353226, BioLegend), anti-CD16 APC/Cy7 (3G8, 302016, BioLegend), anti-CD20 PE (2H7, 555623, BD Biosciences), anti-CD56 A700 (B159, 557919, BD Biosciences), anti-HLA-DR Pacific Blue (L243, 307624, BioLegend), anti-CD11c Percp/Cy5.5 (BU15, 307624, BioLegend), anti-CD1c APC/Cy7 (L161, 331520, BioLegend), anti-CD141 PE (M80, 344104, BioLegend), anti-CD123 PE/Cy7 (6H6, 30601, BioLegend), and anti-CD268 (BAFF-R, 11C1, BioLegend), at a dilution of 1/50. Cells were then fixed and permeabilized with BD Cytofix/Cytoperm plus (BD Biosciences), according to the manufacturer's instructions. Intracellular proteins then were stained by incubation with anti-SPPL2a C-terminus (1/1,000) or anti-SPPL2a epitope 8 (1/1,000), anti-IRF8 (sc-6058, goat, Santa Cruz), anti-STAT1 (sc-345, rabbit, Santa Cruz) or anti-CD74 (ab22603, Abcam) (Pin.1, 1/500) for 45 min at room temperature, in PBS supplemented with 5% BSA and 0.1% saponin, and then for 45 min with goat anti-rabbit Alexa 488 (1/1,000) (Invitrogen) or donkey antigoat Alexa 488 (Invitrogen) in PBS supplemented with 5% BSA and 0.1% saponin. Cells were then processed on an Image Stream-X or BD LSR-II machine. Intraand extracellular CD74 levels in the monocytes, B cells, and T cells of controls and patients were assessed by surface staining with anti-CD20 FITC (347673, BD, clone L27), anti-CD3 BV421 (562426, BD, UCHT1), and anti-surface CD74 (326807, Biolegend, LN2) (if sCD74 was to be assessed) antibodies, then fixed in 2% formaldehyde and washed with PBS supplemented with 0.1% BSA and 0.5% saponin. Anti-intracellular CD74 antibody (Abcam) in PBS supplemented with 0.1% BSA and 0.5% saponin was then added. Lymphocytes and monocytes were gated individually on the basis of their side-scattering (SSC) and forward-scattering (FSC) properties. CD3 + cells were considered to correspond to T cells, and CD20 + cells were identified as T cells.
DC immunophenotyping was performed on cryopreserved cells after thawing, by addition of 1 ml FBS at 37 °C to cryopreservation tubes containing 1 ml frozen PBMCs. The thawed mixture was transferred to a 15-ml conical tube, and 13 ml of PBS, 0.5% BSA, and 2 mM EDTA at room temperature was added. The tubes were centrifuged at 300g for 7 min at 4 °C. The supernatant was discarded, and the cells were resuspended in 10 ml PBS, 0.5% BSA, and 2 mM EDTA at 4 °C and placed on ice. Cell numbers and viability were assessed by trypan blue staining in a counting chamber. 1 × 10 6 -1 × 10 7 cells were transferred to a 5-ml roundbottomed polystyrene tube for staining. The tubes were centrifuged at 300g for 7 min at 4 °C, and the supernatant was discarded. The cells were resuspended at a density of ≤ 1 × 10 7 cells per 20 μ l, and FcR blocking reagent (Miltenyi Biotec, 130-059-901) was added at a 1/10 dilution. The tubes were vortexed to resuspend the cells and left on ice for 15 min before staining. The samples were stained with anti-CD1c (BDCA-1) FITC (AD5-8E7, Miltenyi Biotec, 130-090-507), anti-CD3 PE (UCHT1, mouse IgG1, Beckman Coulter, A07747), anti-CD15 PE (VIMC6, mouse IgM, Miltenyi Biotec, 130-091-375), anti-CD19 PE (HIB19, mouse IgG1 κ , eBioscience, 12-0199-73), anti-CD56 PE (MY31, mouse IgG1 κ , BD Biosciences, 345810), anti-NKp46 PE (BAB281, mouse IgG1, Beckman Coulter, PN IM3711), anti-HLA DR PerCP (L243 (G46-6), muIgG2a κ , BD Biosciences, 347402), anti-CD16 PE/Cy7 (3G8, mouse IgG1, BD Biosciences, 557744), anti-CD11c APC (S-HCL-3, mouse IgG2b κ , BD Biosciences, 333144), anti-CD141 (BDCA-3), VioBlue (AD5-14H12, Miltenyi Biotec, 130-097-325), anti-CLEC9a VioBlue (8F9, Miltenyi Biotec, 130-099-906), and anti-CD14 APC Alexa 750 (M5E2, BioLegend, 301820). All antibodies were used at a dilution of 1/100, except those to CD303 and HLA-DR, which were used at a dilution of 1/50, with ≤ 1 × 10 7 cells/50 μ l. The cells were stained away from direct light for 30 min at 4 °C. They were then washed in 1 ml of 0.5% BSA in PBS at 4 °C; 2 mM EDTA was added, and the cells were centrifuged at 300g for 7 min at 4 °C. The supernatant was discarded. The cells were resuspended in 200 μ l of 0.5% BSA and 2 mM EDTA in PBS at 4 °C, and placed in the dark until being used for flow cytometry. The samples were analyzed on a FACSAria II flow cytometer, and TreeStar FlowJo v9 was used for data analysis.
For progenitor immunophenotyping, classical FSC/SSC gates and zombie yellow viability stain were used to define live cells. Doublets were removed on the basis of FSC-A/FSC-W. From live single cells, hematopoietic progenitors were identified as CD34 + Lin(CD3, CD14, CD16, CD19, CD56, CD66b, CD11c, CD303) -. The progenitor populations studied were further defined by the following gating strategies: HSC/MPP (CD38 -CD45RA -CD10 -), MLP (CD38 -CD45RA + CD10 + ),
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted WGL: Genotype calling was performed with the Affymetrix Power Tools Software Package (http://www.affymetrix.com/estore/ partners_programs/programs/developer/tools/powertools.aff). SNPs were further filtered with population-based filters, using PLINK software, according to the ethnicity of the kindred. We then used the autosomal SNP markers for parametric multipoint linkage analyses with MERLIN.
Flow cytometry data was collected on FACS Diva software and analyzed with the FlowJo v9
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